Brandon Zelasko is a Senior Legal Counsel at ZS, where he advises on complex commercial, regulatory, and compliance matters across the healthcare and life sciences sectors. Based in Chicago, he partners closely with business teams to structure client engagements, manage risk, and support innovative data, digital health, and consulting solutions. Prior to joining ZS, Brandon practiced at Baker McKenzie, focusing on corporate and transactional matters for multinational clients.
Direct‑to‑patient strategies are moving fast—but many fail not because of ambition, but because critical details are missed. In this interactive working session, ZS experts unpack the five foundational truths that determine whether a direct-to-patient (DTP) strategy is set up for real, sustainable impact. Participants will explore how successful DTP strategies require all five elements working together: experience design, clinical design, legal design, user acquisition, and impact measurement. The session, through interactive multidisciplinary Q&A is designed to move beyond theory and provide a practical lens that participants can use to evaluate, design, and refine DTP initiatives in their own rare disease launches.